Try our beta test site
26 studies found for:    ACP-196
Show Display Options
Rank Status Study
1 Active, not recruiting An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma (MCL)
Intervention: Drug: ACP-196 (acalabrutinib)
2 Active, not recruiting ACP-196, a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Condition: Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
Intervention: Drug: ACP-196
3 Recruiting ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies
Conditions: Non-hodgkins Lymphoma;   Multiple Myeloma;   B-All
Intervention: Drug: ACP-196 and ACP-319
4 Active, not recruiting Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)
Condition: Ovarian Cancer
Interventions: Drug: Acalabrutinib;   Drug: acalabrutinib and pembrolizumab combination
5 Recruiting A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: ACP-196 (acalabrutinib)
6 Active, not recruiting Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer
Condition: Metastatic Urothelial Carcinoma
Interventions: Drug: pembrolizumab;   Drug: ACP-196 in combination with pembrolizumab
7 Active, not recruiting Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: pembrolizumab;   Drug: Acalabrutinib
8 Recruiting A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Condition: Glioblastoma Multiforme
Intervention: Drug: ACP-196
9 Active, not recruiting An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma
Condition: Multiple Myeloma (MM)
Intervention: Drug: acalabrutinib
10 Active, not recruiting ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: ACP-196;   Drug: ACP-196 in combination with pembrolizumab
11 Active, not recruiting Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: acalabrutinib;   Drug: ACP-319
12 Completed ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate
Condition: Rheumatoid Arthritis
Interventions: Drug: ACP-196;   Drug: Placebo;   Drug: Methotrexate
13 Active, not recruiting Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Pembrolizumab;   Drug: Acalabrutinib
14 Active, not recruiting An Open-label, Phase 1b Study of Acalabrutinib Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma
Condition: Follicular Lymphoma (FL)
Interventions: Drug: acalabrutinib;   Drug: rituximab (IV)
15 Active, not recruiting Acalabrutinib in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Prolymphocytic Leukemia
Intervention: Drug: acalabrutinib in combination with obinutuzumab
16 Recruiting Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ACP-196;   Drug: ibrutinib
17 Recruiting A Study of Acalabrutinib (ACP-196) in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma (MCL)
Intervention: Drug: acalabrutinib in combination with BR
18 Recruiting Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: acalabrutinib
19 Active, not recruiting ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Richter's Syndrome;   Prolymphocytic Leukemia
Intervention: Drug: acalabrutinib
20 Terminated Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: ACP-196 and Nab-paclitaxel and gemcitabine;   Drug: Nab-paclitaxel and gemcitabine

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.